GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » Asset Turnover

Intersect ENT (Intersect ENT) Asset Turnover : 0.16 (As of Mar. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Intersect ENT's Revenue for the three months ended in Mar. 2022 was $21.6 Mil. Intersect ENT's Total Assets for the quarter that ended in Mar. 2022 was $137.1 Mil. Therefore, Intersect ENT's Asset Turnover for the quarter that ended in Mar. 2022 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. Intersect ENT's annualized ROE % for the quarter that ended in Mar. 2022 was 141.28%. It is also linked to ROA % through Du Pont Formula. Intersect ENT's annualized ROA % for the quarter that ended in Mar. 2022 was -84.02%.


Intersect ENT Asset Turnover Historical Data

The historical data trend for Intersect ENT's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT Asset Turnover Chart

Intersect ENT Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.79 0.76 0.43 0.57

Intersect ENT Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.11 0.16 0.16

Competitive Comparison of Intersect ENT's Asset Turnover

For the Medical Devices subindustry, Intersect ENT's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intersect ENT's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Intersect ENT's Asset Turnover falls into.



Intersect ENT Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Intersect ENT's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=106.748/( (227.381+146.867)/ 2 )
=106.748/187.124
=0.57

Intersect ENT's Asset Turnover for the quarter that ended in Mar. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Mar. 2022 ))/ count )
=21.575/( (146.867+127.393)/ 2 )
=21.575/137.13
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Intersect ENT  (NAS:XENT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Intersect ENT's annulized ROE % for the quarter that ended in Mar. 2022 is

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-115.216/-81.549
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-115.216 / 86.3)*(86.3 / 137.13)*(137.13/ -81.549)
=Net Margin %*Asset Turnover*Equity Multiplier
=-133.51 %*0.6293*-1.6816
=ROA %*Equity Multiplier
=-84.02 %*-1.6816
=141.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Intersect ENT's annulized ROA % for the quarter that ended in Mar. 2022 is

ROA %(Q: Mar. 2022 )
=Net Income/Total Assets
=-115.216/137.13
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-115.216 / 86.3)*(86.3 / 137.13)
=Net Margin %*Asset Turnover
=-133.51 %*0.6293
=-84.02 %

Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Intersect ENT Asset Turnover Related Terms

Thank you for viewing the detailed overview of Intersect ENT's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Intersect ENT (Intersect ENT) Business Description

Traded in Other Exchanges
N/A
Address
1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Executives
Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Intersect ENT (Intersect ENT) Headlines